human
-
One Disease, Many Paths: How Brain Wiring Shapes Huntingtonās Symptoms
HD starts with a single gene change, but its effects travel many roads. New work shows how brain networks breakdown or reroute. Whether movement, thinking, or mood are most affected, we may be able to guide care in a more personalized direction.
-
Do Antidepressants Affect Cognitive Decline? There's More To The Story For Huntington's Disease
Recent research suggests a connection between antidepressant use and increased cognitive decline in people with dementia. However these finding shouldn't be blindly applied to Huntington's disease.
-
Wake up call: Sleep is impacted before Huntingtonās disease symptoms appear
For Sleep Awareness Week (March 9-15), HDBuzz is giving a wake up call to sleep disturbances in Huntingtonās disease. New research suggests sleep changes start early, before other symptoms appearābut there are steps you can take to catch better Z's!
-
Brain Gym: Staying Mentally Active May Slow Huntingtonās Disease
New research suggests that cognitive engagement – keeping your brain busy with activities like reading, puzzles, or learning new skills – could help protect the brain, possibly slowing progression of symptoms of Huntingtonās disease.
-
A New Key to HD? How TDP43 Might Spoil The Show
Like a movie editor removing bloopers, our cells also edit their protein machines to make films worth watching. New research finds the cellās movie editor is distracted in Huntingtonās disease.
By AJ Keefe -
New Insights Into Why Huntingtonās Disease Has Delayed Onset
A highly-anticipated scientific paper has landed! This new work challenges current theories in Huntingtonās disease research, uncovering how runaway CAG repeats erode cell identity in certain types of brain cells, leading to their death.
-
The dust has settled: Sageās dalzanemdor wonāt advance for cognitive impairment
Changes in thinking, learning, and memory are some of the most distressing and impactful in Huntingtonās disease. Sage Therapeutics was advancing their drug dalzanemdor to treat these symptoms, but unfortunately this program will be halted.
-
PROOF-HD study of pridopidine ends with negative result
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntingtonās disease
-
Hereditary Disease Foundation (HDF) conference 2022 ā Day 1
Read updates from clinical trials and scientific research on Huntingtonās disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
-
Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.
By Dr Leora Fox